An Exploratory Phase 1b, Multicenter, Randomized, Open-Label Study to Investigate the Impact of the Administration of Intravenous VH3810109 With or Without Oral Fostemsavir in Combination With Integrase Inhibitor-Based Antiretroviral Therapy on the Viral Reservoir in Adults Living With HIV-1
Latest Information Update: 19 Jan 2026
At a glance
- Drugs GSK 3810109 (Primary) ; Fostemsavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ENTRANCE
- Sponsors ViiV Healthcare
Most Recent Events
- 26 Dec 2025 Planned primary completion date changed from 24 Feb 2027 to 18 Jan 2027.
- 07 Aug 2025 Status changed from not yet recruiting to recruiting.
- 17 Jul 2025 New trial record